Tests a stem cell transplant method for blood cancers
Tests a T cell-depleted stem cell transplant in people with leukemia.
Key facts
- Who runs it
- Masonic Cancer Center, University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 70 people, planned
- Started
- 11 May 2023
- Expected to end
- 30 Nov 2030
- Type of study
- Interventional, 8 groups
- Treatments tested
- Fludarabine
- Busulfan
- Melphalan
- Rituximab
- Levetiracetam
- Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
- Thymoglobulin
- Cyclophosphamide
- Record updated
- 6 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults aged 60 or younger with blood cancers such as acute leukemia or high-risk myelodysplasia. It tests a stem cell transplant with T cells removed.
- Age
- 60 years or younger
- Sex
- All sexes can join
- Disease stage
- Blood cancer confirmed by tissue tests: acute myeloid leukemia, acute lymphoblastic leukemia or lymphoma, or myelodysplasia (IPSS INT-2 or high risk, or refractory anemia with severe low blood counts, transfusion need, or high-risk cytogenetic or molecular features). Good daily function is also needed (Karnofsky 70% or more, or Lansky 50% for those 16 or younger), with adequate organ function.
- Earlier treatment
- People who have had any earlier autologous or allogeneic transplant cannot join.
Main reasons for not taking part
- Pregnant or breastfeeding
- Active uncontrolled infection within 1 week of starting preparative therapy
- Known HIV-positive, or active hepatitis B or C with detectable virus by PCR
- Any earlier autologous or allogeneic transplant
- CML blast crisis, or active central nervous system cancer
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Histological confirmation of hematological malignancies
- Acute leukemias
- Acute Myeloid Leukemia (AML) and related precursor neoplasms
- Favorable risk AML is defined as having one of the following:
- Acute lymphoblastic leukemia (ALL)/lymphoma
- Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features
- Age 60 years of age or younger at the time of consent
- Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age
- Adequate organ function
Who cannot take part
- Any prior autologous or allogeneic transplant
- Active uncontrolled infection within 1 week of starting preparative therapy
- Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR
- Active central nervous system malignancy
- Pregnant or breastfeeding
- CML blast crisis
Where in United States
- University of Minnesota/Masonic Cancer CenterMinneapolis, United StatesContact: Margaret MacMillanTaking people
About the trial
What the trial wants to find out
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.
The 8 groups in the trial
- Arm 1A: Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI Regimen, Closed to AccrualTreatment being tested
Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Treatment: Fludarabine, Rituximab, Levetiracetam, and Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
- Arm 2A: Fludarabine (flu), Busulfan (bu), Flu/Bu Regimen, Closed to AccrualTreatment being tested
Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Treatment: Fludarabine, Busulfan, Rituximab, and Levetiracetam
- Arm 3A: Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients OnlyTreatment being tested
Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia. , Closed to Accrual
Treatment: Fludarabine, Busulfan, Melphalan, Rituximab, and Levetiracetam
- Arm 1B: ATG, Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI RegimenTreatment being tested
Patients will be treated on the most medically appropriate regimen with a preference for ATG/Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Treatment: Fludarabine, Rituximab, Levetiracetam, and Thymoglobulin
- Arm 2B: ATG, Fludarabine (flu), Busulfan (bu), Flu/Bu RegimenTreatment being tested
Patients will be treated on the most medically appropriate regimen with a preference for ATG/Flu/BU/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Treatment: Fludarabine, Busulfan, Rituximab, Levetiracetam, and Thymoglobulin
- Arm 3B: ATG, Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients OnlyTreatment being tested
ATG/Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia.
Treatment: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, and Thymoglobulin
- Arm 4B: ATG, Busulfan (BU), Cyclophosphamide (CY)Treatment being tested
Patients will be treated on the most medically appropriate regimen with a preference for ATG/BU/CY Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Treatment: Busulfan, Rituximab, Levetiracetam, Thymoglobulin, and Cyclophosphamide
- Arm 5B: ATG, Cyclophosphamide (CY), Total Body Irradiation (TBI)Treatment being tested
Patients will be treated on the most medically appropriate regimen with a preference for ATG/CY/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Treatment: Rituximab, Levetiracetam, Thymoglobulin, and Cyclophosphamide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
- Plain-language title
- Tests a stem cell transplant method for blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 April 2026